Evidence map›Paper›PMID 25952951›Full record

ArticleEye (London, England)2015

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.

G A Kim, T H Rim, S C Lee, S H Byeon, H J Koh, S S Kim, C S Lee

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Central serous chorioretinopathy: Treatment.Taiwan journal of ophthalmology
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

G A KimThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
T H RimThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
S C LeeThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
S H ByeonThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
H J KohThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
S S KimThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
C S LeeThe Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Shinchon Severance Hospital, Seoul, South Korea.
Yonsei University · KRSeverance Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate factors associated with good response to intravitreal bevacizumab (IVB) in central serous chorioretinopathy (CSC) patients.

methodsWe retrospectively reviewed 42 eyes of CSC patients of symptom duration more than 3 months who received a single or multiple successive IVBs on an as-needed basis (0.05 ml, 1.25 mg). High responders (HRs) were defined as complete resolution of subretinal fluid (SRF) on spectral domain optical coherence tomography (SD-OCT). Moderate responders (MRs) were defined as SRF resolution of 50-99% of pretreatment volume and poor responders (PRs) as SRF resolution <50%. Clinical, SD-OCT, fluorescein, and indocyanine green angiography findings were analyzed to find factors associated with HR. Descriptive statistics for all demographic and clinical variables were calculated, and comparisons were made using Wilcoxon's matched-pairs signed-rank test, the Mann-Whitney U-test for means with continuous data, Pearson's χ(2) test, and Fisher's exact test for categorical data.

resultsThe mean number of IVB was 1.9. At postoperative 1 month, there were 10 (24%) HRs, 18 (43%) MRs, and 14 (33%) PRs. At the last follow-up (the mean 8.6 months), there were 25 HRs (60%), 9 MRs (21%), and 8 PRs (19%). Thicker subfoveal choroid (P=0.036), smaller lesion diameter (P=0.019), and better baseline best-corrected visual acuity (P=0.002) predicted HRs at postoperative 1 month. HR at the last follow-up was associated with classic pattern fluorescein angiography finding.

conclusionsSuboptimal effects of IVB on persistent CSC suggest primary IVB on selective cases with better vision, smaller lesion, and thicker choroid at baseline.

Indexed as

AdultAngiogenesis InhibitorsBevacizumabCentral Serous ChorioretinopathyFemaleFluorescein AngiographyHumansIntravitreal InjectionsMaleMiddle AgedRetrospective StudiesSubretinal FluidTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID25952951
PMCPMC4469674
OpenAlexW1001739598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.